JP2009541236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009541236A5 JP2009541236A5 JP2009515748A JP2009515748A JP2009541236A5 JP 2009541236 A5 JP2009541236 A5 JP 2009541236A5 JP 2009515748 A JP2009515748 A JP 2009515748A JP 2009515748 A JP2009515748 A JP 2009515748A JP 2009541236 A5 JP2009541236 A5 JP 2009541236A5
- Authority
- JP
- Japan
- Prior art keywords
- branched
- moiety
- group
- phenyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000000217 alkyl group Chemical group 0.000 claims 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 23
- 125000003545 alkoxy group Chemical group 0.000 claims 19
- 125000004432 carbon atom Chemical group C* 0.000 claims 19
- -1 (phenyl) ethyl Chemical group 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 239000002773 nucleotide Substances 0.000 claims 12
- 125000003729 nucleotide group Chemical group 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 10
- HQBUPOAKJGJGCD-UHFFFAOYSA-N 3h-imidazo[4,5-c]quinolin-4-amine Chemical class NC1=NC2=CC=CC=C2C2=C1N=CN2 HQBUPOAKJGJGCD-UHFFFAOYSA-N 0.000 claims 7
- 239000013603 viral vector Substances 0.000 claims 7
- 241000700605 Viruses Species 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 238000001727 in vivo Methods 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 229960005486 vaccine Drugs 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 241000700618 Vaccinia virus Species 0.000 claims 3
- 230000002238 attenuated effect Effects 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical class C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 0 CCCCCCCCC[C@](CCC(*C(C1C2*C([Ru])=**C1)NCC)C2(CC)C1CCCCCC1)*(C)(C)C Chemical compound CCCCCCCCC[C@](CCC(*C(C1C2*C([Ru])=**C1)NCC)C2(CC)C1CCCCCC1)*(C)(C)C 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06360028 | 2006-06-20 | ||
| US85296406P | 2006-10-20 | 2006-10-20 | |
| PCT/EP2007/005303 WO2007147529A2 (en) | 2006-06-20 | 2007-06-15 | Recombinant viral vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009541236A JP2009541236A (ja) | 2009-11-26 |
| JP2009541236A5 true JP2009541236A5 (enExample) | 2010-07-29 |
Family
ID=38657260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515748A Ceased JP2009541236A (ja) | 2006-06-20 | 2007-06-15 | 組換えウイルスワクチン |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100129403A1 (enExample) |
| EP (1) | EP2029169A2 (enExample) |
| JP (1) | JP2009541236A (enExample) |
| KR (1) | KR101141333B1 (enExample) |
| CN (1) | CN101472610A (enExample) |
| AU (1) | AU2007263281B2 (enExample) |
| BR (1) | BRPI0713711A2 (enExample) |
| CA (1) | CA2656266C (enExample) |
| CR (1) | CR10571A (enExample) |
| IL (1) | IL195683A0 (enExample) |
| MA (1) | MA30581B1 (enExample) |
| MX (1) | MX2008016036A (enExample) |
| NO (1) | NO20090194L (enExample) |
| RU (1) | RU2453335C2 (enExample) |
| WO (1) | WO2007147529A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012002628B1 (pt) | 2009-08-07 | 2021-09-08 | Transgene Sa | Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes |
| WO2012145577A1 (en) * | 2011-04-20 | 2012-10-26 | Merial Limited | Adjuvanted rabies vaccine with improved viscosity profile |
| TWI575070B (zh) | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| WO2013045658A1 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
| TW201321016A (zh) | 2011-09-29 | 2013-06-01 | Transgene Sa | 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二） |
| CA2878800A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterial antigen vaccine |
| CN103409451A (zh) * | 2013-06-28 | 2013-11-27 | 扬州维克斯生物科技有限公司 | 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法 |
| RU2695462C2 (ru) | 2014-01-09 | 2019-07-23 | Трансген Са | Гибридизация гетероолигомерных микобактериальных антигенов |
| ES2909957T3 (es) | 2014-07-16 | 2022-05-11 | Transgene | Virus oncolítico para la expresión de moduladores de puntos de control inmunitarios |
| CN107949397A (zh) | 2015-02-13 | 2018-04-20 | 特兰斯吉恩股份有限公司 | 免疫治疗疫苗和抗体组合治疗 |
| WO2017191147A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| US20190328869A1 (en) | 2016-10-10 | 2019-10-31 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| AU2017387549B2 (en) | 2016-12-28 | 2023-07-06 | Transgene Sa | Oncolytic viruses and therapeutic molecules |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| JP2022547234A (ja) | 2019-08-29 | 2022-11-10 | アステラス製薬株式会社 | 遺伝子操作された腫瘍溶解性ワクシニアウイルスおよびその使用方法 |
| US20230256057A1 (en) | 2020-07-13 | 2023-08-17 | Transgene | Treatment of immune depression |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
| AU2023326730A1 (en) | 2022-08-18 | 2025-03-13 | Transgene | Chimeric poxviruses |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| DE69029212T2 (de) | 1989-02-27 | 1997-05-22 | Riker Laboratories Inc | 4-Amino-1H-Imidazo(4,5-c)chinoline als antivirale Mittel |
| US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| ATE247163T1 (de) | 1991-03-07 | 2003-08-15 | Virogenetics Corp | Gentechnologisch hergestellter stamm für impfstoffe |
| GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6331539B1 (en) * | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| UA77152C2 (en) | 1999-09-25 | 2006-11-15 | Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma | |
| GB0023008D0 (en) * | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| JP2005519990A (ja) | 2001-10-12 | 2005-07-07 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物 |
| ATE491471T1 (de) * | 2002-03-19 | 2011-01-15 | Powderject Res Ltd | Adjuvantien für dns impstoffe basierend auf imidazochinoline |
| US20050048072A1 (en) * | 2003-08-25 | 2005-03-03 | 3M Innovative Properties Company | Immunostimulatory combinations and treatments |
| EP1804583A4 (en) * | 2004-10-08 | 2009-05-20 | 3M Innovative Properties Co | ADJUVANT FOR DNA VACCINE |
-
2007
- 2007-06-15 JP JP2009515748A patent/JP2009541236A/ja not_active Ceased
- 2007-06-15 EP EP07764675A patent/EP2029169A2/en not_active Withdrawn
- 2007-06-15 WO PCT/EP2007/005303 patent/WO2007147529A2/en not_active Ceased
- 2007-06-15 MX MX2008016036A patent/MX2008016036A/es active IP Right Grant
- 2007-06-15 AU AU2007263281A patent/AU2007263281B2/en not_active Ceased
- 2007-06-15 CA CA2656266A patent/CA2656266C/en not_active Expired - Fee Related
- 2007-06-15 CN CNA2007800232312A patent/CN101472610A/zh active Pending
- 2007-06-15 KR KR1020087030973A patent/KR101141333B1/ko not_active Expired - Fee Related
- 2007-06-15 US US12/306,227 patent/US20100129403A1/en not_active Abandoned
- 2007-06-15 BR BRPI0713711-7A patent/BRPI0713711A2/pt not_active IP Right Cessation
- 2007-06-15 RU RU2009101387/15A patent/RU2453335C2/ru not_active IP Right Cessation
-
2008
- 2008-12-03 IL IL195683A patent/IL195683A0/en unknown
-
2009
- 2009-01-09 MA MA31557A patent/MA30581B1/fr unknown
- 2009-01-13 NO NO20090194A patent/NO20090194L/no not_active Application Discontinuation
- 2009-01-16 CR CR10571A patent/CR10571A/es not_active Application Discontinuation